Company Profile

Member Since

  • 2019

Membership Category

  • Pharmaceutical Sales and Mfg

Contact Information

Norwood, MA 02062
United States

Description

  • Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its industry leading pipeline of endocannabinoid system-targeting drug candidates. The Company's lead product candidate, lenabasum, is a novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The pipeline includes CRB-4001, a peripherally-restricted, selective CB1 inverse agonist with potential indications for NASH, primary biliary cholangitis, IPF, among others.

Number of Employees

  • 50 - 499